Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. Currently, surgical resection is the only potentially curative treatment. Unfortunately, less than 20% of PDAC patients are eligible for surgical resection at diagnosis. In the past few decades, neoadjuvant chemotherapy treatment (NCT) has been investigated as a way to downstage PDAC tumors for surgical resection. Fluorescence-guided surgery (FGS) is a technique that can aid in increasing complete resection rates by enhancing the tumor through passive or active targeting of a contrast agent. In active targeting, a probe (e.g., antibody) binds a protein differentially upregulated in the tumor compared to normal tissue. Mucin 16 (MUC16), a transmembrane glycoprotein, has recently been explored as an FGS target in preclinical tumor models. However, the impact of chemotherapy on MUC16 expression is unknown.Methods: To investigate this issue, immunohistochemistry was performed on PDAC patient samples. Results: We found that MUC16 expression was retained after NCT in patient samples (mean expression = 5.7) with minimal change in expression between the matched diagnostic (mean expression = 3.66) and PDAC NCT patient samples (mean expression = 4.5).Conclusions: This study suggests that MUC16 is a promising target for FGS and other targeted therapies in PDAC patients treated with NCT.
背景/目的：胰腺导管腺癌（PDAC）预后较差。目前，手术切除是唯一可能实现根治的治疗方式。遗憾的是，诊断时仅有不到20%的PDAC患者符合手术切除条件。过去几十年来，新辅助化疗（NCT）作为一种降低PDAC肿瘤分期以实现手术切除的方法被广泛研究。荧光引导手术（FGS）是一种通过造影剂的被动或主动靶向增强肿瘤显影，从而提高完全切除率的技术。在主动靶向中，探针（如抗体）会与肿瘤中相较于正常组织差异上调的蛋白质结合。跨膜糖蛋白黏蛋白16（MUC16）近期在临床前肿瘤模型中已被探索作为FGS的靶点。然而，化疗对MUC16表达的影响尚不明确。 方法：为探究此问题，我们对PDAC患者样本进行了免疫组织化学分析。 结果：研究发现，在患者样本中，MUC16表达在接受NCT后得以保留（平均表达量=5.7），且匹配的诊断样本（平均表达量=3.66）与接受NCT的PDAC患者样本（平均表达量=4.5）之间的表达变化极小。 结论：本研究表明，对于接受NCT治疗的PDAC患者，MUC16是FGS及其他靶向治疗中具有潜力的靶点。
MUC16 Retention after Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma
肿瘤(癌症)患者之家